{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T14:48:34Z","timestamp":1787237314403,"version":"build-2736575974"},"reference-count":148,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100014584","name":"Universit\u00e4tsmedizin der Johannes Gutenberg-Universit\u00e4t Mainz","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100014584","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Thyroid Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Thyroid hormones influence the function of essentially every system of the body, including the cardiovascular and metabolic system. Thyroid hormone replacement with levothyroxine (LT4) is the mainstay of pharmacological management for people with (especially clinically overt) hypothyroidism, and it is important to ensure the cardiovascular and metabolic safety of this treatment. This is especially so as in hypothyroidism, cardiometabolic risk factors and cardiovascular disease are highly prevalent conditions and will often coexist in an individual patient. Accordingly, we have reviewed the cardiometabolic consequences of hypothyroidism and intervention with thyroid hormone replacement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Main body<\/jats:title>\n                    <jats:p>Numerous observational studies and meta-analyses have described multiple potentially adverse cardiometabolic consequences of hypothyroidism, including exacerbation of cardiovascular and metabolic risk factors (especially dyslipidaemia), functional impairment of the heart and vasculature (including accelerated atherosclerosis) and increased risk of advanced cardiovascular outcomes. LT4 usually improves cardiometabolic risk factors in people with hypothyroidism and some (but not all) studies have reported improved vascular and cardiac function in LT4-treated populations. Observational data have suggested the possibility of improved cardiometabolic outcomes with LT4 treatment, particularly in younger people with hypothyroidism, although data from randomised, controlled trials are needed here. Importantly, LT4 (with or without additional triiodothyronine) appears to be safe from a cardiovascular perspective, as long as overtreatment and iatrogenic thyrotoxicosis are avoided.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Overall, the current evidence base supports intervention with LT4 to protect the cardiometabolic health of people with hypothyroidism who require thyroid hormone replacement, although more data on long-term clinical outcomes are needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13044-025-00233-y","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T18:02:50Z","timestamp":1747677770000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Hypothyroidism: playing the cardiometabolic risk concerto"],"prefix":"10.1186","volume":"18","author":[{"given":"George J.","family":"Kahaly","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youshuo","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Persani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"issue":"Suppl 2","key":"233_CR1","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s12325-019-01080-8","volume":"36","author":"L Chiovato","year":"2019","unstructured":"Chiovato L, Magri F, Carl\u00e9 A. Hypothyroidism in context: where we\u2019ve been and where we\u2019re going. Adv Ther. 2019;36(Suppl 2):47\u201358.","journal-title":"Adv Ther"},{"key":"233_CR2","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrendo.2018.18","volume":"14","author":"PN Taylor","year":"2018","unstructured":"Taylor PN, Albrecht D, Scholz A, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol. 2018;14:301\u201316.","journal-title":"Nat Rev Endocrinol"},{"key":"233_CR3","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1001\/jama.2019.9052","volume":"322","author":"B Biondi","year":"2019","unstructured":"Biondi B, Cappola AR, Cooper DS. Subclinical hypothyroidism: a review. JAMA. 2019;322:153\u201360.","journal-title":"JAMA"},{"key":"233_CR4","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1089\/thy.2010.0298","volume":"21","author":"C McQuade","year":"2011","unstructured":"McQuade C, Skugor M, Brennan DM, Hoar B, Stevenson C, Hoogwerf BJ. Hypothyroidism and moderate subclinical hypothyroidism are associated with increased all-cause mortality independent of coronary heart disease risk factors: a PreCIS database study. Thyroid. 2011;21:837\u201343.","journal-title":"Thyroid"},{"issue":"16","key":"233_CR5","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1016\/j.jacc.2018.02.045","volume":"71","author":"S Razvi","year":"2018","unstructured":"Razvi S, Jabbar A, Pingitore A, et al. Thyroid hormones and cardiovascular function and diseases. J Am Coll Cardiol. 2018;71(16):1781\u201396.","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"233_CR6","volume":"16","author":"D Z\u00fa\u00f1iga","year":"2024","unstructured":"Z\u00fa\u00f1iga D, Balasubramanian S, Mehmood KT, Al-Baldawi S, Z\u00fa\u00f1iga SG. Hypothyroidism and cardiovascular disease: a review. Cureus. 2024;16(1): e52512.","journal-title":"Cureus"},{"key":"233_CR7","doi-asserted-by":"publisher","first-page":"2467","DOI":"10.1001\/archinte.165.21.2467","volume":"165","author":"JP Walsh","year":"2005","unstructured":"Walsh JP, Bremner AP, Bulsara MK, et al. Subclinical thyroid dysfunction as a risk factor for cardiovascular disease. Arch Intern Med. 2005;165:2467\u201372.","journal-title":"Arch Intern Med"},{"key":"233_CR8","doi-asserted-by":"publisher","first-page":"2361","DOI":"10.1016\/j.jacc.2022.11.005","volume":"80","author":"M Vaduganathan","year":"2022","unstructured":"Vaduganathan M, Mensah GA, Turco JV, Fuster V, Roth GA. The global burden of cardiovascular diseases and risk: a compass for future health. J Am Coll Cardiol. 2022;80:2361\u201371.","journal-title":"J Am Coll Cardiol"},{"key":"233_CR9","unstructured":"World Health Organization. Cardiovascular Diseases. Available at https:\/\/www.who.int\/health-topics\/cardiovascular-disease. Accessed Sept 2024."},{"key":"233_CR10","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1210\/jc.2009-1749","volume":"95","author":"S Razvi","year":"2010","unstructured":"Razvi S, Weaver JU, Vanderpump MP, Pearce SH. The incidence of ischemic heart disease and mortality in people with subclinical hypothyroidism: reanalysis of the Whickham Survey cohort. J Clin Endocrinol Metab. 2010;95:1734\u201340.","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR11","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1001\/archinte.167.14.1526","volume":"167","author":"G Iervasi","year":"2007","unstructured":"Iervasi G, Molinaro S, Landi P, et al. Association between increased mortality and mild thyroid dysfunction in cardiac patients. Arch Intern Med. 2007;167:1526\u201332.","journal-title":"Arch Intern Med"},{"key":"233_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1161\/01.HYP.5.1.112","volume":"5","author":"I Saito","year":"1983","unstructured":"Saito I, Ito K, Saruta T. Hypothyroidism as a cause of hypertension. Hypertension. 1983;5:112\u20135.","journal-title":"Hypertension"},{"key":"233_CR13","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1007\/s40618-016-0488-7","volume":"39","author":"E Piantanida","year":"2016","unstructured":"Piantanida E, Gallo D, Veronesi G, et al. Masked hypertension in newly diagnosed hypothyroidism: a pilot study. J Endocrinol Invest. 2016;39:1131\u20138.","journal-title":"J Endocrinol Invest"},{"key":"233_CR14","first-page":"61","volume":"19","author":"JJ Wang","year":"2022","unstructured":"Wang JJ, Zhuang ZH, Yu CQ, et al. Assessment of causal direction between thyroid function and cardiometabolic health: a Mendelian randomization study. J Geriatr Cardiol. 2022;19:61\u201370.","journal-title":"J Geriatr Cardiol"},{"key":"233_CR15","doi-asserted-by":"publisher","DOI":"10.1186\/1756-6614-1-3","volume":"1","author":"K Saltiki","year":"2008","unstructured":"Saltiki K, Voidonikola P, Stamatelopoulos K, Mantzou E, Papamichael C, Alevizaki M. Association of thyroid function with arterial pressure in normotensive and hypertensive euthyroid individuals: A cross-sectional study. Thyroid Res. 2008;1: 3.","journal-title":"Thyroid Res"},{"key":"233_CR16","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/sj.jhh.1002091","volume":"20","author":"A Iqbal","year":"2006","unstructured":"Iqbal A, Figenschau Y, Jorde R. Blood pressure in relation to serum thyrotropin: The Troms\u00f8 study. J Hum Hypertens. 2006;20:932\u20136.","journal-title":"J Hum Hypertens"},{"key":"233_CR17","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1038\/jhh.2009.44","volume":"24","author":"D Liu","year":"2010","unstructured":"Liu D, Jiang F, Shan Z, et al. A cross-sectional survey of relationship between serum TSH level and blood pressure. J Hum Hypertens. 2010;24:134\u20138.","journal-title":"J Hum Hypertens"},{"key":"233_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10153318","volume":"10","author":"J Kim","year":"2021","unstructured":"Kim J, Prasitlumkum N, Randhawa S, Banerjee D. Association between subclinical hypothyroidism and incident hypertension in women: a systematic review and meta-analysis. J Clin Med. 2021;10: 3318.","journal-title":"J Clin Med"},{"key":"233_CR19","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4158\/EP13237.OR","volume":"20","author":"Y Ye","year":"2014","unstructured":"Ye Y, Xie H, Zeng Y, Zhao X, Tian Z, Zhang S. Association between subclinical hypothyroidism and blood pressure\u2013a meta-analysis of observational studies. Endocr Pract. 2014;20:150\u20138.","journal-title":"Endocr Pract"},{"key":"233_CR20","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1507\/endocrj.EJ20-0796","volume":"68","author":"X Ding","year":"2021","unstructured":"Ding X, Zhao Y, Zhu CY, et al. The association between subclinical hypothyroidism and metabolic syndrome: an update meta-analysis of observational studies. Endocr J. 2021;68:1043\u201356.","journal-title":"Endocr J"},{"key":"233_CR21","doi-asserted-by":"crossref","unstructured":"Teixeira P de F, Reuters VS, Ferreira MM, et al. Lipid profile in different degrees of hypothyroidism and effects of levothyroxine replacement in mild thyroid failure. Transl Res. 2008;151:224\u201331.","DOI":"10.1016\/j.trsl.2007.12.006"},{"key":"233_CR22","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s12944-015-0092-4","volume":"14","author":"K Zha","year":"2015","unstructured":"Zha K, Zuo C, Wang A, et al. LDL in patients with subclinical hypothyroidism shows increased lipid peroxidation. Lipids Health Dis. 2015;14:95.","journal-title":"Lipids Health Dis"},{"key":"233_CR23","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1055\/s-0034-1389997","volume":"46","author":"M Khazan","year":"2014","unstructured":"Khazan M, Amouzegar A, Gharibzadeh S, Mehran L, Tohidi M, Azizi F. Prevalence of hypothyroidism in patients with dyslipidemia: Tehran Thyroid Study (TTS). Horm Metab Res. 2014;46:980\u20134.","journal-title":"Horm Metab Res"},{"key":"233_CR24","doi-asserted-by":"publisher","first-page":"R159","DOI":"10.1530\/EJE-16-0611","volume":"176","author":"V Pergialiotis","year":"2017","unstructured":"Pergialiotis V, Konstantopoulos P, Prodromidou A, Florou V, Papantoniou N, Perrea DN. Management of endocrine disease: The impact of subclinical hypothyroidism on anthropometric characteristics, lipid, glucose and hormonal profile of PCOS patients: a systematic review and meta-analysis. Eur J Endocrinol. 2017;176:R159\u201366.","journal-title":"Eur J Endocrinol"},{"key":"233_CR25","doi-asserted-by":"publisher","first-page":"1432","DOI":"10.12659\/MSM.891163","volume":"20","author":"XL Liu","year":"2014","unstructured":"Liu XL, He S, Zhang SF, et al. Alteration of lipid profile in subclinical hypothyroidism: a meta-analysis. Med Sci Monit. 2014;20:1432\u201341.","journal-title":"Med Sci Monit"},{"key":"233_CR26","first-page":"428","volume":"46","author":"Y Treister-Goltzman","year":"2021","unstructured":"Treister-Goltzman Y, Yarza S, Peleg R. Lipid profile in mild subclinical hypothyroidism: systematic review and meta-analysis. Minerva Endocrinol (Torino). 2021;46:428\u201340.","journal-title":"Minerva Endocrinol (Torino)"},{"key":"233_CR27","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1055\/a-1463-3198","volume":"53","author":"Y Xing","year":"2021","unstructured":"Xing Y, Chen J, Liu J, Ma H. The impact of subclinical hypothyroidism on patients with polycystic ovary syndrome: a meta-analysis. Horm Metab Res. 2021;53:382\u201390.","journal-title":"Horm Metab Res"},{"key":"233_CR28","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1159\/000485619","volume":"83","author":"SF de Medeiros","year":"2018","unstructured":"de Medeiros SF, de Medeiros MAS, Ormond CM, Barbosa JS, Yamamoto MMW. Subclinical hypothyroidism impact on the characteristics of patients with polycystic ovary syndrome. a meta-analysis of observational studies. Gynecol Obstet Invest. 2018;83:105\u201315.","journal-title":"Gynecol Obstet Invest."},{"key":"233_CR29","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1530\/EJE-08-0797","volume":"160","author":"E Maratou","year":"2009","unstructured":"Maratou E, Hadjidakis DJ, Kollias A, et al. Studies of insulin resistance in patients with clinical and subclinical hypothyroidism. Eur J Endocrinol. 2009;160:785\u201390.","journal-title":"Eur J Endocrinol"},{"key":"233_CR30","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3389\/fendo.2018.00474","volume":"9","author":"AG Cicatiello","year":"2018","unstructured":"Cicatiello AG, Di Girolamo D, Dentice M. Metabolic effects of the intracellular regulation of thyroid hormone: old players, new concepts. Front Endocrinol (Lausanne). 2018;9:474.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"233_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1186\/s12916-016-0693-4","volume":"14","author":"L Chaker","year":"2016","unstructured":"Chaker L, Ligthart S, Korevaar TI, et al. Thyroid function and risk of type 2 diabetes: a population-based prospective cohort study. BMC Med. 2016;14:150.","journal-title":"BMC Med"},{"key":"233_CR32","doi-asserted-by":"publisher","first-page":"718","DOI":"10.4093\/dmj.2018.0222","volume":"43","author":"SW Kim","year":"2019","unstructured":"Kim SW, Jeon JH, Moon JS, et al. Low-normal free thyroxine levels in euthyroid male are associated with prediabetes. Diabetes Metab J. 2019;43:718\u201326.","journal-title":"Diabetes Metab J"},{"key":"233_CR33","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0066711","volume":"8","author":"F Brandt","year":"2013","unstructured":"Brandt F, Thvilum M, Almind D, et al. Morbidity before and after the diagnosis of hyperthyroidism: a nationwide register-based study. PLoS ONE. 2013;8: e66711.","journal-title":"PLoS ONE"},{"key":"233_CR34","volume":"15","author":"SL Vemula","year":"2023","unstructured":"Vemula SL, Aramadaka S, Mannam R, et al. The impact of hypothyroidism on diabetes mellitus and its complications: A Comprehensive Review. Cureus. 2023;15: e40447.","journal-title":"Cureus"},{"key":"233_CR35","doi-asserted-by":"publisher","first-page":"873","DOI":"10.2147\/DMSO.S355727","volume":"15","author":"Y Li","year":"2022","unstructured":"Li Y, Yi M, Deng X, Li W, Chen Y, Zhang X. Evaluation of the thyroid characteristics and correlated factors in hospitalized patients with newly diagnosed type 2 diabetes. Diabetes Metab Syndr Obes. 2022;15:873\u201384.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"233_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11030626","volume":"11","author":"S Agrawal","year":"2022","unstructured":"Agrawal S, Makuch S, Dr\u00f3\u017cd\u017c M, et al. The impact of hypoglycemia on patients with diabetes mellitus: a cross-sectional analysis. J Clin Med. 2022;11: 626.","journal-title":"J Clin Med"},{"key":"233_CR37","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1089\/met.2015.0065","volume":"14","author":"A Eftekharzadeh","year":"2016","unstructured":"Eftekharzadeh A, Khamseh ME, Farshchi A, Malek M. The Association Between Subclinical Hypothyroidism and metabolic syndrome as defined by the ATP III Criteria. Metab Syndr Relat Disord. 2016;14:137\u201344.","journal-title":"Metab Syndr Relat Disord"},{"key":"233_CR38","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.661160","volume":"12","author":"J He","year":"2021","unstructured":"He J, Lai Y, Yang J, et al. The relationship between thyroid function and metabolic syndrome and its components: a cross-sectional study in a Chinese Population. Front Endocrinol (Lausanne). 2021;12: 661160.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"233_CR39","doi-asserted-by":"publisher","first-page":"6754","DOI":"10.1038\/s41598-017-07004-2","volume":"7","author":"CH Chang","year":"2017","unstructured":"Chang CH, Yeh YC, Caffrey JL, Shih SR, Chuang LM, Tu YK. Metabolic syndrome is associated with an increased incidence of subclinical hypothyroidism - A Cohort Study. Sci Rep. 2017;7:6754.","journal-title":"Sci Rep"},{"key":"233_CR40","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3109\/07435800.2015.1108332","volume":"41","author":"L Yang","year":"2016","unstructured":"Yang L, Lv X, Yue F, Wei D, Liu W, Zhang T. Subclinical hypothyroidism and the risk of metabolic syndrome: A meta-analysis of observational studies. Endocr Res. 2016;41:158\u201365.","journal-title":"Endocr Res"},{"key":"233_CR41","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1159\/000351249","volume":"2","author":"KA Iwen","year":"2013","unstructured":"Iwen KA, Schr\u00f6der E, Brabant G. Thyroid hormones and the metabolic syndrome. Eur Thyroid J. 2013;2:83\u201392.","journal-title":"Eur Thyroid J"},{"key":"233_CR42","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2147\/IJGM.S206983","volume":"12","author":"M R\u00edos-Prego","year":"2019","unstructured":"R\u00edos-Prego M, Anibarro L, S\u00e1nchez-Sobrino P. Relationship between thyroid dysfunction and body weight: a not so evident paradigm. Int J Gen Med. 2019;12:299\u2013304.","journal-title":"Int J Gen Med"},{"key":"233_CR43","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1007\/s12020-021-02677-2","volume":"72","author":"Y Wang","year":"2021","unstructured":"Wang Y, Lin H, Li Q, et al. Association between different obesity phenotypes and hypothyroidism: a study based on a longitudinal health management cohort. Endocrine. 2021;72:688\u201398.","journal-title":"Endocrine"},{"key":"233_CR44","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s12902-021-00743-4","volume":"21","author":"M Mahdavi","year":"2021","unstructured":"Mahdavi M, Amouzegar A, Mehran L, Madreseh E, Tohidi M, Azizi F. Investigating the prevalence of primary thyroid dysfunction in obese and overweight individuals: Tehran thyroid study. BMC Endocr Disord. 2021;21:89.","journal-title":"BMC Endocr Disord"},{"issue":"Suppl 6","key":"233_CR45","doi-asserted-by":"publisher","first-page":"s29","DOI":"10.7861\/clinmedicine.14-6-s29","volume":"14","author":"A Jabbar","year":"2014","unstructured":"Jabbar A, Razvi S. Thyroid disease and vascular risk. Clin Med (Lond). 2014;14(Suppl 6):s29-32.","journal-title":"Clin Med (Lond)"},{"key":"233_CR46","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1097\/HJH.0000000000002655","volume":"39","author":"P Cai","year":"2021","unstructured":"Cai P, Peng Y, Chen Y, Wang Y, Wang X. Blood pressure characteristics of subclinical hypothyroidism: an observation study combined with office blood pressure and 24-h ambulatory blood pressure. J Hypertens. 2021;39:453\u201360.","journal-title":"J Hypertens"},{"key":"233_CR47","doi-asserted-by":"publisher","unstructured":"Ettleson MD, Penna GCE, Wan W, Bense\u00f1or IM, Laiteerapong N, Bianco AC. TSH trajectories during levothyroxine treatment in the Brazilian longitudinal study of adult health (ELSA-Brasil) cohort. J Clin Endocrinol Metab. 2024 (advance publication online, https:\/\/doi.org\/10.1210\/clinem\/dgae294).","DOI":"10.1210\/clinem\/dgae294"},{"key":"233_CR48","volume":"14","author":"R Maiti","year":"2022","unstructured":"Maiti R, Mohanty RR, Mishra A, Dey A, Verma N. Levothyroxine therapy and predictors of cardiovascular risk in clinical hypothyroidism: a prospective cohort study. Cureus. 2022;14: e30969.","journal-title":"Cureus"},{"key":"233_CR49","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/147070","volume":"2015","author":"Z Gluvic","year":"2015","unstructured":"Gluvic Z, Sudar E, Tica J, et al. Effects of levothyroxine replacement therapy on parameters of metabolic syndrome and atherosclerosis in hypothyroid patients: a prospective pilot study. Int J Endocrinol. 2015;2015: 147070.","journal-title":"Int J Endocrinol"},{"key":"233_CR50","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1210\/jcem.87.5.8464","volume":"87","author":"E Fommei","year":"2002","unstructured":"Fommei E, Iervasi G. The role of thyroid hormone in blood pressure homeostasis: evidence from short-term hypothyroidism in humans. J Clin Endocrinol Metab. 2002;87:1996\u20132000.","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpcardiol.2023.102204","volume":"49","author":"B Darouei","year":"2024","unstructured":"Darouei B, Amani-Beni R, Abhari AP, Fakhrolmobasheri M, Shafie D, Heidarpour M. Systematic review and meta-analysis of levothyroxine effect on blood pressure in patients with subclinical hypothyroidism. Curr Probl Cardiol. 2024;49: 102204.","journal-title":"Curr Probl Cardiol"},{"key":"233_CR52","doi-asserted-by":"publisher","first-page":"454","DOI":"10.3389\/fendo.2018.00454","volume":"9","author":"W He","year":"2018","unstructured":"He W, Li S, Zhang JA, Zhang J, Mu K, Li XM. Effect of levothyroxine on blood pressure in patients with subclinical hypothyroidism: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2018;9:454.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"233_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.913749","volume":"13","author":"C Zhao","year":"2022","unstructured":"Zhao C, Wang Y, Xiao L, Li L. Effect of levothyroxine on older patients with subclinical hypothyroidism: a systematic review and meta-analysis. Front Endocrinol (Lausanne). 2022;13: 913749.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"233_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.cca.2022.01.006","volume":"27","author":"X Su","year":"2022","unstructured":"Su X, Peng H, Chen X, Wu X, Xijie W, Wang B. Hyperlipidemia and hypothyroidism. Clin Chim Acta. 2022;27:61\u201370.","journal-title":"Clin Chim Acta"},{"key":"233_CR55","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1089\/10507250050137743","volume":"10","author":"GJ Kahaly","year":"2000","unstructured":"Kahaly GJ. Cardiovascular and atherogenic aspects of subclinical hypothyroidism. Thyroid. 2000;10:665\u201379.","journal-title":"Thyroid"},{"key":"233_CR56","doi-asserted-by":"publisher","DOI":"10.1530\/EC-21-0002","volume":"11","author":"H Liu","year":"2022","unstructured":"Liu H, Peng D. Update on dyslipidemia in hypothyroidism: the mechanism of dyslipidemia in hypothyroidism. Endocr Connect. 2022;11: e210002.","journal-title":"Endocr Connect"},{"key":"233_CR57","doi-asserted-by":"publisher","DOI":"10.3390\/ijms222312797","volume":"22","author":"M Mavromati","year":"2021","unstructured":"Mavromati M, Jornayvaz FR. Hypothyroidism-associated dyslipidemia: potential molecular mechanisms leading to NAFLD. Int J Mol Sci. 2021;22: 12797.","journal-title":"Int J Mol Sci"},{"key":"233_CR58","doi-asserted-by":"publisher","first-page":"76","DOI":"10.2174\/1874192401105010076","volume":"5","author":"CV Rizos","year":"2011","unstructured":"Rizos CV, Elisaf MS, Liberopoulos EN. Effects of thyroid dysfunction on lipid profile. Open Cardiovasc Med J. 2011;5:76\u201384.","journal-title":"Open Cardiovasc Med J"},{"key":"233_CR59","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1185\/03007995.2015.1094044","volume":"31","author":"P Liu","year":"2015","unstructured":"Liu P, Liu R, Chen X, et al. Can levothyroxine treatment reduce urinary albumin excretion rate in patients with early type 2 diabetic nephropathy and subclinical hypothyroidism? A randomized double-blind and placebo-controlled study. Curr Med Res Opin. 2015;31:2233\u201340.","journal-title":"Curr Med Res Opin"},{"key":"233_CR60","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1210\/jc.2003-031669","volume":"89","author":"F Monzani","year":"2004","unstructured":"Monzani F, Caraccio N, Koz\u00e0kow\u00e0 M, et al. Effect of levothyroxine replacement on lipid profile and intima-media thickness in subclinical hypothyroidism: a double-blind, placebo- controlled study. J Clin Endocrinol Metab. 2004;89:2099\u2013106.","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR61","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1089\/thy.2016.0010","volume":"26","author":"M Zhao","year":"2016","unstructured":"Zhao M, Liu L, Wang F, et al. A Worthy Finding: Decrease in total cholesterol and low-density lipoprotein cholesterol in treated mild subclinical hypothyroidism. Thyroid. 2016;26:1019\u201329.","journal-title":"Thyroid"},{"key":"233_CR62","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1210\/jc.2006-1869","volume":"92","author":"S Razvi","year":"2007","unstructured":"Razvi S, Ingoe L, Keeka G, Oates C, McMillan C, Weaver JU. The beneficial effect of L-thyroxine on cardiovascular risk factors, endothelial function, and quality of life in subclinical hypothyroidism: randomized, crossover trial. J Clin Endocrinol Metab. 2007;92:1715\u201323.","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR63","doi-asserted-by":"publisher","first-page":"1533","DOI":"10.1210\/jcem.87.4.8378","volume":"87","author":"N Caraccio","year":"2002","unstructured":"Caraccio N, Ferrannini E, Monzani F. Lipoprotein profile in subclinical hypothyroidism: response to levothyroxine replacement, a randomized placebo-controlled study. J Clin Endocrinol Metab. 2002;87:1533\u20138.","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR64","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1186\/s13104-023-06516-7","volume":"16","author":"A Ostadrahimi","year":"2023","unstructured":"Ostadrahimi A, Manzari T, Gohari-Lasaki S, et al. Effects of levothyroxine replacement therapy on insulin resistance in patients with untreated primary hypothyroidism. BMC Res Notes. 2023;16:237.","journal-title":"BMC Res Notes"},{"key":"233_CR65","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1016\/j.ando.2014.06.002","volume":"75","author":"O Deyneli","year":"2014","unstructured":"Deyneli O, Akp\u0131nar IN, Meri\u00e7liler OS, G\u00f6z\u00fc H, Y\u0131ld\u0131z ME, Akal\u0131n NS. Effects of levothyroxine treatment on insulin sensitivity, endothelial function and risk factors of atherosclerosis in hypothyroid women. Ann Endocrinol (Paris). 2014;75:220\u20136.","journal-title":"Ann Endocrinol (Paris)"},{"key":"233_CR66","first-page":"20","volume":"61","author":"Z Velija-Asimi","year":"2007","unstructured":"Velija-Asimi Z, Karamehic J. The effects of treatment of subclinical hypothyroidism on metabolic control and hyperinsulinemia. Med Arh. 2007;61:20\u20131.","journal-title":"Med Arh"},{"key":"233_CR67","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s12020-011-9446-5","volume":"40","author":"I Kowalska","year":"2011","unstructured":"Kowalska I, Borawski J, Niko\u0142ajuk A, et al. Insulin sensitivity, plasma adiponectin and sICAM-1 concentrations in patients with subclinical hypothyroidism: response to levothyroxine therapy. Endocrine. 2011;40:95\u2013101.","journal-title":"Endocrine"},{"key":"233_CR68","doi-asserted-by":"publisher","first-page":"433","DOI":"10.4183\/aeb.2012.433","volume":"8","author":"I Ersoy","year":"2012","unstructured":"Ersoy I, Banu KK, Bagci O, et al. Effects of levothyroxine treatment on cardiovascular risk profile and carotid intima media thickness in patients with subclinical hypothyroidism. Acta Endocrinologica-Bucharest. 2012;8:433\u201342.","journal-title":"Acta Endocrinologica-Bucharest"},{"key":"233_CR69","doi-asserted-by":"publisher","first-page":"dgaa672","DOI":"10.1210\/clinem\/dgaa672","volume":"105","author":"A Kotwal","year":"2020","unstructured":"Kotwal A, Cortes T, Genere N, et al. Treatment of thyroid dysfunction and serum lipids: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2020;105:dgaa672.","journal-title":"J Clin Endocrinol Metab."},{"key":"233_CR70","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2023-076388","volume":"384","author":"KS Kim","year":"2024","unstructured":"Kim KS, Hong S, Han K, Park CY. Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study. BMJ. 2024;384: e076388.","journal-title":"BMJ"},{"key":"233_CR71","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s13105-023-00954-4","volume":"79","author":"P Sangro","year":"2023","unstructured":"Sangro P, de la Torre AM, Sangro B, D\u2019Avola D. Metabolic dysfunction-associated fatty liver disease (MAFLD): an update of the recent advances in pharmacological treatment. J Physiol Biochem. 2023;79:869\u201379.","journal-title":"J Physiol Biochem"},{"key":"233_CR72","doi-asserted-by":"publisher","DOI":"10.1016\/j.dsx.2024.103034","volume":"18","author":"MS Kuchay","year":"2024","unstructured":"Kuchay MS, Isaacs S, Misra A. Intrahepatic hypothyroidism in MASLD: Role of liver-specific thyromimetics including resmetirom. Diabetes Metab Syndr. 2024;18: 103034.","journal-title":"Diabetes Metab Syndr"},{"key":"233_CR73","doi-asserted-by":"publisher","first-page":"909","DOI":"10.1007\/s12020-014-0372-1","volume":"48","author":"D Yaz\u0131c\u0131","year":"2015","unstructured":"Yaz\u0131c\u0131 D, \u00d6zben B, Toprak A, et al. Effects of restoration of the euthyroid state on epicardial adipose tissue and carotid intima media thickness in subclinical hypothyroid patients. Endocrine. 2015;48:909\u201315.","journal-title":"Endocrine"},{"key":"233_CR74","doi-asserted-by":"publisher","first-page":"963","DOI":"10.2147\/DMSO.S219438","volume":"13","author":"D Cappellani","year":"2020","unstructured":"Cappellani D, Macchia E, Falorni A, Marchetti P. Insulin autoimmune syndrome (Hirata Disease): a comprehensive review fifty years after its first description. Diabetes Metab Syndr Obes. 2020;13:963\u201378.","journal-title":"Diabetes Metab Syndr Obes"},{"key":"233_CR75","doi-asserted-by":"publisher","first-page":"335","DOI":"10.21037\/atm.2018.07.32","volume":"6","author":"S Censi","year":"2018","unstructured":"Censi S, Mian C, Betterle C. Insulin autoimmune syndrome: from diagnosis to clinical management. Ann Transl Med. 2018;6:335.","journal-title":"Ann Transl Med"},{"key":"233_CR76","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1530\/EJE-22-0523","volume":"187","author":"H Alwan","year":"2022","unstructured":"Alwan H, Villoz F, Feller M, et al. Subclinical thyroid dysfunction and incident diabetes: a systematic review and an individual participant data analysis of prospective cohort studies. Eur J Endocrinol. 2022;187:S35-46.","journal-title":"Eur J Endocrinol"},{"key":"233_CR77","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0135233","volume":"10","author":"C Han","year":"2015","unstructured":"Han C, He X, Xia X, et al. Subclinical hypothyroidism and type 2 diabetes: a systematic review and meta-analysis. PLoS ONE. 2015;10: e0135233.","journal-title":"PLoS ONE"},{"key":"233_CR78","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1210\/clinem\/dgac006","volume":"107","author":"OH Roa Due\u00f1as","year":"2022","unstructured":"Roa Due\u00f1as OH, Van der Burgh AC, Ittermann T, et al. Thyroid function and the risk of prediabetes and type 2 diabetes. J Clin Endocrinol Metab. 2022;107:1789\u201398.","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR79","doi-asserted-by":"publisher","DOI":"10.1038\/srep12212","volume":"5","author":"J Wu","year":"2015","unstructured":"Wu J, Yue S, Geng J, et al. Relationship between diabetic retinopathy and subclinical hypothyroidism: a meta-analysis. Sci Rep. 2015;5: 12212.","journal-title":"Sci Rep"},{"key":"233_CR80","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1515\/CCLM.2005.121","volume":"43","author":"S Stanicka","year":"2005","unstructured":"Stanicka S, Vondra K, Pelikanova T, Vlcek P, Hill M, Zamrazil V. Insulin sensitivity and counter-regulatory hormones in hypothyroidism and during thyroid hormone replacement therapy. Clin Chem Lab Med. 2005;43:715\u201320.","journal-title":"Clin Chem Lab Med"},{"key":"233_CR81","first-page":"443","volume":"129","author":"J Roth","year":"2019","unstructured":"Roth J, M\u00fcller N, Kuniss N, Wolf G, M\u00fcller UA, et al. Association between glycaemic control and the intake of thiazide diuretics, beta blockers and levothyroxine in people without diabetes. Exp Clin Endocrinol Diabetes. 2019;129:443\u20138.","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"233_CR82","volume":"15","author":"PK Manshahia","year":"2023","unstructured":"Manshahia PK, Nahar S, Kanda S, et al. Systematic review to gauge the effect of levothyroxine substitution on progression of diabetic nephropathy in patients with hypothyroidism and type 2 diabetes Mellitus. Cureus. 2023;15: e44729.","journal-title":"Cureus"},{"key":"233_CR83","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23020786","volume":"23","author":"G Fahed","year":"2022","unstructured":"Fahed G, Aoun L, Bou Zerdan M, et al. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. Int J Mol Sci. 2022;23: 786.","journal-title":"Int J Mol Sci"},{"key":"233_CR84","doi-asserted-by":"crossref","unstructured":"Guembe MJ, Fernandez-Lazaro CI, Sayon-Orea C, Toledo E, Moreno-Iribas C; RIVANA Study Investigators. Risk for cardiovascular disease associated with metabolic syndrome and its components: a 13-year prospective study in the RIVANA cohort. Cardiovasc Diabetol. 2020;19:195.","DOI":"10.1186\/s12933-020-01166-6"},{"key":"233_CR85","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.obmed.2018.12.008","volume":"13","author":"BF Garcia","year":"2019","unstructured":"Garcia BF, da Veiga GL, Alves BCA, Gehrke FS, Fonseca FLA. Metabolic effects caused by sodium levothyroxine in subclinical hypothyroidism patients with low HDL. Obes Med. 2019;13:26\u20138.","journal-title":"Obes Med"},{"key":"233_CR86","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1177\/0300060516664242","volume":"45","author":"JH An","year":"2017","unstructured":"An JH, Song KH, Kim DL, Kim SK. Effects of thyroid hormone withdrawal on metabolic and cardiovascular parameters during radioactive iodine therapy in differentiated thyroid cancer. J Int Med Res. 2017;45:38\u201350.","journal-title":"J Int Med Res"},{"key":"233_CR87","doi-asserted-by":"publisher","first-page":"4106816","DOI":"10.1155\/2019\/4106816","volume":"2019","author":"S Razvi","year":"2019","unstructured":"Razvi S, Bhana S, Mrabeti S. Challenges in interpreting thyroid stimulating hormone results in the diagnosis of thyroid dysfunction. J Thyroid Res. 2019;2019:4106816.","journal-title":"J Thyroid Res"},{"key":"233_CR88","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.1001\/jama.2018.13770","volume":"320","author":"M Feller","year":"2018","unstructured":"Feller M, Snel M, Moutzouri E, et al. Association of thyroid hormone therapy with quality of life and thyroid-related symptoms in patients with subclinical hypothyroidism: a systematic review and meta-analysis. JAMA. 2018;320:1349\u201359.","journal-title":"JAMA"},{"key":"233_CR89","unstructured":"American Thyroid Association. Thyroid and weight. Available at https:\/\/www.thyroid.org\/thyroid-and-weight\/. Accessed Sept 2024."},{"key":"233_CR90","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.4158\/EP14072.OR","volume":"20","author":"SY Lee","year":"2014","unstructured":"Lee SY, Braverman LE, Pearce EN. Changes in body weight after treatment of primary hypothyroidism with levothyroxine. Endocr Pract. 2014;20:1122\u20138.","journal-title":"Endocr Pract"},{"key":"233_CR91","doi-asserted-by":"publisher","DOI":"10.1530\/EC-23-0314","volume":"12","author":"BR Medici","year":"2023","unstructured":"Medici BR, Nygaard B, la Cour JL, et al. Effects of levothyroxine substitution therapy on hunger and food intake in individuals with hypothyroidism. Endocr Connect. 2023;12: e230314.","journal-title":"Endocr Connect"},{"key":"233_CR92","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1089\/thy.2014.0028","volume":"24","author":"J Jonklaas","year":"2014","unstructured":"Jonklaas J, Bianco AC, Bauer AJ, et al. Guidelines for the treatment of hypothyroidism: prepared by the American Thyroid Association Task Force on Thyroid Hormone Replacement. Thyroid. 2014;24:1670\u2013751.","journal-title":"Thyroid"},{"key":"233_CR93","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1161\/CIRCULATIONAHA.123.065485","volume":"149","author":"N Sattar","year":"2024","unstructured":"Sattar N, Neeland IJ, McGuire DK. Obesity and cardiovascular disease: a new dawn. Circulation. 2024;149:1621\u20133.","journal-title":"Circulation"},{"key":"233_CR94","doi-asserted-by":"publisher","first-page":"38","DOI":"10.4103\/2277-9175.178783","volume":"5","author":"N Niknam","year":"2016","unstructured":"Niknam N, Khalili N, Khosravi E, Nourbakhsh M. Endothelial dysfunction in patients with subclinical hypothyroidism and the effects of treatment with levothyroxine. Adv Biomed Res. 2016;5:38.","journal-title":"Adv Biomed Res"},{"key":"233_CR95","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1055\/a-1018-9564","volume":"51","author":"N Gong","year":"2019","unstructured":"Gong N, Gao C, Chen X, Fang Y, Tian L. Endothelial function in patients with subclinical hypothyroidism: a meta-analysis. Horm Metab Res. 2019;51:691\u2013702.","journal-title":"Horm Metab Res"},{"key":"233_CR96","doi-asserted-by":"publisher","first-page":"4579","DOI":"10.1038\/s41598-018-22897-3","volume":"8","author":"K Yao","year":"2018","unstructured":"Yao K, Zhao T, Zeng L, et al. Non-invasive markers of cardiovascular risk in patients with subclinical hypothyroidism: a systematic review and meta-analysis of 27 case control studies. Sci Rep. 2018;8:4579.","journal-title":"Sci Rep"},{"key":"233_CR97","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCHEARTFAILURE.118.005266","volume":"11","author":"L Kannan","year":"2018","unstructured":"Kannan L, Shaw PA, Morley MP, et al. Thyroid dysfunction in heart failure and cardiovascular outcomes. Circ Heart Fail. 2018;11: e005266.","journal-title":"Circ Heart Fail"},{"key":"233_CR98","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jjcc.2012.08.017","volume":"61","author":"X Chen","year":"2013","unstructured":"Chen X, Zhang N, Cai Y, Shi J. Evaluation of left ventricular diastolic function using tissue Doppler echocardiography and conventional doppler echocardiography in patients with subclinical hypothyroidism aged <60 years: a meta-analysis. J Cardiol. 2013;61:8\u201315.","journal-title":"J Cardiol"},{"key":"233_CR99","doi-asserted-by":"publisher","first-page":"392","DOI":"10.20945\/2359-3997000000052","volume":"62","author":"VV Nakova","year":"2018","unstructured":"Nakova VV, Krstevska B, Kostovska ES, Vaskova O, Ismail LG. The effect of levothyroxine treatment on left ventricular function in subclinical hypothyroidism. Arch Endocrinol Metab. 2018;62:392\u20138.","journal-title":"Arch Endocrinol Metab"},{"key":"233_CR100","doi-asserted-by":"publisher","first-page":"4999","DOI":"10.1038\/s41598-018-22970-x","volume":"8","author":"Z Yao","year":"2018","unstructured":"Yao Z, Gao X, Liu M, et al. Diffuse myocardial injuries are present in subclinical hypothyroidism: a clinical study using myocardial T1-mapping quantification. Sci Rep. 2018;8:4999.","journal-title":"Sci Rep"},{"key":"233_CR101","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2017-016053","volume":"7","author":"T Zhao","year":"2017","unstructured":"Zhao T, Chen B, Zhou Y, et al. Effect of levothyroxine on the progression of carotid intima-media thickness in subclinical hypothyroidism patients: a meta-analysis. BMJ Open. 2017;7: e016053.","journal-title":"BMJ Open"},{"key":"233_CR102","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.atherosclerosis.2012.10.070","volume":"227","author":"N Gao","year":"2013","unstructured":"Gao N, Zhang W, Zhang YZ, Yang Q, Chen SH. Carotid intima-media thickness in patients with subclinical hypothyroidism: a meta-analysis. Atherosclerosis. 2013;227:18\u201325.","journal-title":"Atherosclerosis"},{"key":"233_CR103","doi-asserted-by":"publisher","first-page":"643","DOI":"10.5551\/jat.39917","volume":"24","author":"M Aziz","year":"2017","unstructured":"Aziz M, Kandimalla Y, Machavarapu A, et al. Effect of Thyroxin Treatment on Carotid Intima-Media Thickness (CIMT) Reduction in Patients with Subclinical Hypothyroidism (SCH): a meta-analysis of clinical trials. J Atheroscler Thromb. 2017;24:643\u201359.","journal-title":"J Atheroscler Thromb"},{"key":"233_CR104","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1016\/j.biopha.2006.07.010","volume":"60","author":"F Franzoni","year":"2006","unstructured":"Franzoni F, Galetta F, Fallahi P, et al. Effect of L-thyroxine treatment on left ventricular function in subclinical hypothyroidism. Biomed Pharmacother. 2006;60:431\u20136.","journal-title":"Biomed Pharmacother"},{"key":"233_CR105","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1210\/jcem.86.3.7291","volume":"86","author":"F Monzani","year":"2001","unstructured":"Monzani F, Di Bello V, Caraccio N, et al. Effect of levothyroxine on cardiac function and structure in subclinical hypothyroidism: a double blind, placebo-controlled study. J Clin Endocrinol Metab. 2001;86:1110\u20135.","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR106","first-page":"1697","volume":"116","author":"X Lu","year":"2003","unstructured":"Lu X, Huang J, Zhang X, et al. Effects of thyroxine on cardiac function and lymphocyte beta-adrenoceptors in patients with chronic congestive heart failure. Chin Med J (Engl). 2003;116:1697\u2013700.","journal-title":"Chin Med J (Engl)"},{"key":"233_CR107","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1016\/S0002-9343(96)00281-1","volume":"101","author":"P Moruzzi","year":"1996","unstructured":"Moruzzi P, Doria E, Agostoni PG. Medium-term effectiveness of L-thyroxine treatment in idiopathic dilated cardiomyopathy. Am J Med. 1996;101:461\u20137.","journal-title":"Am J Med"},{"key":"233_CR108","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/0002-9149(94)90011-6","volume":"73","author":"P Moruzzi","year":"1994","unstructured":"Moruzzi P, Doria E, Agostoni PG, et al. Usefulness of L-thyroxine to improve cardiac and exercise performance in idiopathic dilated cardiomyopathy. Am J Cardiol. 1994;73:374\u20138.","journal-title":"Am J Cardiol"},{"key":"233_CR109","doi-asserted-by":"publisher","unstructured":"Gencer, Moutzouri E, Blum MR, et al. The impact of levothyroxine on cardiac function in older adults with mild subclinical hypothyroidism: a randomized clinical trial. Am J Med. 2020 (advance publication online, https:\/\/doi.org\/10.1016\/j.amjmed.2020.01.018).","DOI":"10.1016\/j.amjmed.2020.01.018"},{"key":"233_CR110","doi-asserted-by":"publisher","first-page":"960","DOI":"10.12659\/MSM.889621","volume":"19","author":"S Ilic","year":"2013","unstructured":"Ilic S, Tadic M, Ivanovic B, Caparevic Z, Trbojevic B, Celic V. Left and right ventricular structure and function in subclinical hypothyroidism: the effects of one-year levothyroxine treatment. Med Sci Monit. 2013;19:960\u20138.","journal-title":"Med Sci Monit"},{"key":"233_CR111","doi-asserted-by":"publisher","first-page":"E607","DOI":"10.1210\/jc.2014-2942","volume":"100","author":"A Madathil","year":"2015","unstructured":"Madathil A, Hollingsworth KG, Blamire AM, et al. Levothyroxine improves abnormal cardiac bioenergetics in subclinical hypothyroidism: a cardiac magnetic resonance spectroscopic study. J Clin Endocrinol Metab. 2015;100:E607\u201310.","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR112","first-page":"657","volume":"29","author":"J Haloot","year":"2023","unstructured":"Haloot J, Mahmoud M, Kabbani M, et al. Cardiovascular outcomes of levothyroxine supplementation in patients with heart failure with preserved ejection fraction. J Cardiac Fail. 2023;29:657.","journal-title":"J Cardiac Fail"},{"key":"233_CR113","unstructured":"Gavrila A, American Thyroid Association. Clinical thyroidology for the public. Hypothyroidism. Levothyroxine treatment increases mortality in patients with heart failure. Available at https:\/\/www.thyroid.org\/patient-thyroid-information\/ct-for-patients\/may-2019\/vol-12-issue-5-p-9-10\/. Accessed Sept 2024."},{"key":"233_CR114","doi-asserted-by":"publisher","first-page":"2674","DOI":"10.1210\/clinem\/dgac417","volume":"107","author":"X Wang","year":"2022","unstructured":"Wang X, Wang H, Li Q, et al. Effect of levothyroxine supplementation on the cardiac morphology and function in patients with subclinical hypothyroidism: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2022;107:2674\u201383.","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR115","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1530\/EJE-19-0006","volume":"180","author":"M Lillevang-Johansen","year":"2019","unstructured":"Lillevang-Johansen M, Abrahamsen B, J\u00f8rgensen HL, Brix TH, Heged\u00fcs L. Duration of over- and under-treatment of hypothyroidism is associated with increased cardiovascular risk. Eur J Endocrinol. 2019;180:407\u201316.","journal-title":"Eur J Endocrinol"},{"key":"233_CR116","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1089\/thy.2018.0320","volume":"29","author":"M Lillevang-Johansen","year":"2019","unstructured":"Lillevang-Johansen M, Abrahamsen B, J\u00f8rgensen HL, Brix TH, Heged\u00fcs L. Duration of hyperthyroidism and lack of sufficient treatment are associated with increased cardiovascular risk. Thyroid. 2019;29:332\u201340.","journal-title":"Thyroid"},{"key":"233_CR117","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1210\/jc.2014-2990","volume":"100","author":"WH Chen","year":"2015","unstructured":"Chen WH, Chen YK, Lin CL, Yeh JH, Kao CH. Hashimoto\u2019s thyroiditis, risk of coronary heart disease, and L-thyroxine treatment: a nationwide cohort study. J Clin Endocrinol Metab. 2015;100:109\u201314.","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR118","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0129793","volume":"10","author":"MN Andersen","year":"2015","unstructured":"Andersen MN, Olsen AM, Madsen JC, et al. Levothyroxine substitution in patients with subclinical hypothyroidism and the risk of myocardial infarction and mortality. PLoS One. 2015;10: e0129793.","journal-title":"PLoS One"},{"key":"233_CR119","doi-asserted-by":"publisher","first-page":"4170","DOI":"10.1210\/jc.2016-2226","volume":"101","author":"MN Andersen","year":"2016","unstructured":"Andersen MN, Olsen AS, Madsen JC, et al. Long-term outcome in levothyroxine treated patients with subclinical hypothyroidism and concomitant heart disease. J Clin Endocrinol Metab. 2016;101:4170\u20137.","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR120","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/archinternmed.2012.1159","volume":"172","author":"S Razvi","year":"2012","unstructured":"Razvi S, Weaver JU, Butler TJ, Pearce SH. Levothyroxine treatment of subclinical hypothyroidism, fatal and nonfatal cardiovascular events, and mortality. Arch Intern Med. 2012;172:811\u20137.","journal-title":"Arch Intern Med"},{"key":"233_CR121","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1210\/clinem\/dgaa777","volume":"106","author":"CC Peng","year":"2021","unstructured":"Peng CC, Huang HK, Wu BB, Chang RH, Tu YK, Munir KM. Association of thyroid hormone therapy with mortality in subclinical hypothyroidism: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2021;106:292\u2013303.","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR122","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1007\/s12020-022-02982-4","volume":"75","author":"SA Paschou","year":"2022","unstructured":"Paschou SA, Bletsa E, Stampouloglou PK, et al. Thyroid disorders and cardiovascular manifestations: an update. Endocrine. 2022;75:672\u201383.","journal-title":"Endocrine"},{"key":"233_CR123","doi-asserted-by":"publisher","first-page":"2988","DOI":"10.1210\/jc.2018-00279","volume":"103","author":"MR Blum","year":"2018","unstructured":"Blum MR, Gencer B, Adam L, et al. Impact of thyroid hormone therapy on atherosclerosis in the elderly with subclinical hypothyroidism: a randomized trial. J Clin Endocrinol Metab. 2018;103:2988\u201397.","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR124","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.amjcard.2018.03.371","volume":"122","author":"S Moon","year":"2018","unstructured":"Moon S, Kong SH, Choi HS, et al. Relation of subclinical hypothyroidism is associated with cardiovascular events and all-cause mortality in adults with high cardiovascular risk. Am J Cardiol. 2018;122:571\u20137.","journal-title":"Am J Cardiol"},{"key":"233_CR125","doi-asserted-by":"publisher","unstructured":"Fang H, Zhao R, Cui S, Wan W. Sex differences in major cardiovascular outcomes and fractures in patients with subclinical thyroid dysfunction: a systematic review and meta-analysis. Aging (Albany NY). 2022 (advance publication online, 2022;14:https:\/\/doi.org\/10.18632\/aging.204352).","DOI":"10.18632\/aging.204352"},{"key":"233_CR126","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1530\/EJE-14-0464","volume":"171","author":"TH Kim","year":"2014","unstructured":"Kim TH, Choi HS, Bae JC, et al. Subclinical hypothyroidism in addition to common risk scores for prediction of cardiovascular disease: a 10-year community-based cohort study. Eur J Endocrinol. 2014;171:649\u201357.","journal-title":"Eur J Endocrinol"},{"key":"233_CR127","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.ijcard.2017.09.192","volume":"253","author":"Y Lee","year":"2018","unstructured":"Lee Y, Lim YH, Shin JH, Park J, Shin J. Impact of subclinical hypothyroidism on clinical outcomes following percutaneous coronary intervention. Int J Cardiol. 2018;253:155\u201360.","journal-title":"Int J Cardiol"},{"key":"233_CR128","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.cjca.2017.10.021","volume":"34","author":"Y Sato","year":"2018","unstructured":"Sato Y, Yoshihisa A, Kimishima Y, et al. Subclinical hypothyroidism is associated with adverse prognosis in heart failure patients. Can J Cardiol. 2018;34:80\u20137.","journal-title":"Can J Cardiol"},{"key":"233_CR129","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1089\/thy.2017.0414","volume":"28","author":"S Moon","year":"2018","unstructured":"Moon S, Kim MJ, Yu JM, Yoo HJ, Park YJ. Subclinical hypothyroidism and the risk of cardiovascular disease and all-cause mortality: a meta-analysis of prospective cohort studies. Thyroid. 2018;28:1101\u201310.","journal-title":"Thyroid"},{"key":"233_CR130","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1001\/jama.2010.1361","volume":"304","author":"N Rodondi","year":"2010","unstructured":"Rodondi N, den Elzen WP, Bauer DC, et al. Subclinical hypothyroidism and the risk of coronary heart disease and mortality. JAMA. 2010;304:1365\u201374.","journal-title":"JAMA"},{"key":"233_CR131","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1186\/s12916-017-0777-9","volume":"15","author":"Y Ning","year":"2017","unstructured":"Ning Y, Cheng YJ, Liu LJ, et al. What is the association of hypothyroidism with risks of cardiovascular events and mortality? A meta-analysis of 55 cohort studies involving 1,898,314 participants. BMC Med. 2017;15:21.","journal-title":"BMC Med"},{"key":"233_CR132","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.117.311603","volume":"121","author":"A Bano","year":"2017","unstructured":"Bano A, Chaker L, Mattace-Raso FUS, et al. Thyroid function and the risk of atherosclerotic cardiovascular morbidity and mortality: The Rotterdam Study. Circ Res. 2017;121:1392\u2013400.","journal-title":"Circ Res"},{"key":"233_CR133","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/cen.13383","volume":"87","author":"X Zhang","year":"2017","unstructured":"Zhang X, Xie Y, Ding C, et al. Subclinical hypothyroidism and risk of cerebral small vessel disease: A hospital-based observational study. Clin Endocrinol (Oxf). 2017;87:581\u20136.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"233_CR134","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1007\/s10654-014-9946-8","volume":"29","author":"L Chaker","year":"2014","unstructured":"Chaker L, Baumgartner C, Ikram MA, et al. Subclinical thyroid dysfunction and the risk of stroke: a systematic review and meta-analysis. Eur J Epidemiol. 2014;29:791\u2013800.","journal-title":"Eur J Epidemiol"},{"key":"233_CR135","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1089\/thy.2023.0548","volume":"33","author":"S Razvi","year":"2023","unstructured":"Razvi S. Cardiac Safety and Efficacy of Combination Levothyroxine and L-Triiodothyronine in Patients with Athyreotic Hypothyroidism: Reassuring Initial Data but More Is Needed. Thyroid. 2023;33:1393\u20134.","journal-title":"Thyroid"},{"key":"233_CR136","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1080\/03007995.2021.1984219","volume":"37","author":"U Gottwald-Hostalek","year":"2021","unstructured":"Gottwald-Hostalek U, Kahaly GJ. Triiodothyronine alongside levothyroxine in the management of hypothyroidism? Curr Med Res Opin. 2021;37:2099\u2013106.","journal-title":"Curr Med Res Opin"},{"key":"233_CR137","unstructured":"Shahid MA, Ashraf MA, Sharma S. Physiology, thyroid hormone. StatPearls. Available at https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK500006\/. Accessed Nov 2024."},{"key":"233_CR138","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.816566","volume":"13","author":"BA Bjerkreim","year":"2022","unstructured":"Bjerkreim BA, Hammerstad SS, Gulseth HL, et al. Effect of liothyronine treatment on quality of life in female hypothyroid patients with residual symptoms on levothyroxine therapy: a randomized crossover study. Front Endocrinol (Lausanne). 2022;13: 816566.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"233_CR139","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1590\/2359-3997000000192","volume":"60","author":"J Kaminski","year":"2016","unstructured":"Kaminski J, Miasaki FY, Paz-Filho G, Graf H, Carvalho GA. Treatment of hypothyroidism with levothyroxine plus liothyronine: a randomized, double-blind, crossover study. Arch Endocrinol Metab. 2016;60:562\u201372.","journal-title":"Arch Endocrinol Metab"},{"key":"233_CR140","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1089\/thy.2021.0609","volume":"32","author":"M Tharmapoopathy","year":"2022","unstructured":"Tharmapoopathy M, Thavarajah A, Kenny RPW, et al. Efficacy and safety of triiodothyronine treatment in cardiac surgery or cardiovascular diseases: a systematic review and meta-analysis of randomized controlled trials. Thyroid. 2022;32:879\u201396.","journal-title":"Thyroid"},{"key":"233_CR141","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1210\/jc.2006-1552","volume":"92","author":"R Napoli","year":"2007","unstructured":"Napoli R, Guardasole V, Angelini V, et al. Acute effects of triiodothyronine on endothelial function in human subjects. J Clin Endocrinol Metab. 2007;92:250\u20134.","journal-title":"J Clin Endocrinol Metab"},{"key":"233_CR142","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1089\/thy.2023.0135","volume":"33","author":"B Biondi","year":"2023","unstructured":"Biondi B, Pucci M, Pontieri G, Formisano P, Esposito R. Preliminary results of a double-blind randomized controlled trial evaluating the cardiometabolic effects of levothyroxine and liothyronine compared to levothyroxine with placebo in athyreotic low-risk thyroid cancer patients. Thyroid. 2023;33:1402\u201313.","journal-title":"Thyroid"},{"key":"233_CR143","doi-asserted-by":"publisher","first-page":"19","DOI":"10.2174\/157489008783331625","volume":"3","author":"A Pingitore","year":"2008","unstructured":"Pingitore A, Iervasi G. Triiodothyronine (T3) effects on cardiovascular system in patients with heart failure. Recent Pat Cardiovasc Drug Discov. 2008;3:19\u201327.","journal-title":"Recent Pat Cardiovasc Drug Discov"},{"key":"233_CR144","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S0002-9149(97)00950-8","volume":"81","author":"MA Hamilton","year":"1998","unstructured":"Hamilton MA, Stevenson LW, Fonarow GC, et al. Safety and hemodynamic effects of intravenous triiodothyronine in advanced congestive heart failure. Am J Cardiol. 1998;81:443\u20137.","journal-title":"Am J Cardiol"},{"key":"233_CR145","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1111\/cen.12648","volume":"83","author":"P Holmager","year":"2015","unstructured":"Holmager P, Schmidt U, Mark P, et al. Long-term L-Triiodothyronine (T3) treatment in stable systolic heart failure patients: a randomised, double-blind, cross-over, placebo-controlled intervention study. Clin Endocrinol (Oxf). 2015;83:931\u20137.","journal-title":"Clin Endocrinol (Oxf)"},{"key":"233_CR146","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2021.571765","volume":"12","author":"Y Zhao","year":"2021","unstructured":"Zhao Y, Wang W, Zhang K, Tang YD. Association between low T3 syndrome and poor prognosis in adult patients with acute myocarditis. Front Endocrinol (Lausanne). 2021;12: 571765.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"233_CR147","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1080\/03007995.2024.2435460","volume":"40","author":"U Gottwald-Hostalek","year":"2024","unstructured":"Gottwald-Hostalek U, Tayrouz Y. A review of the safety of triiodothyronine in combination with levothyroxine for the management of hypothyroidism. Curr Med Res Opin. 2024;40:2109\u201316.","journal-title":"Curr Med Res Opin"},{"key":"233_CR148","doi-asserted-by":"publisher","first-page":"R76","DOI":"10.1530\/EC-19-0096","volume":"8","author":"M von Hafe","year":"2019","unstructured":"von Hafe M, Neves JS, Vale C, Borges-Canha M, Leite-Moreira A. The impact of thyroid hormone dysfunction on ischemic heart disease. Endocr Connect. 2019;8:R76-90.","journal-title":"Endocr Connect"}],"container-title":["Thyroid Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-025-00233-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13044-025-00233-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13044-025-00233-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T18:02:54Z","timestamp":1747677774000},"score":1,"resource":{"primary":{"URL":"https:\/\/thyroidresearchjournal.biomedcentral.com\/articles\/10.1186\/s13044-025-00233-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":148,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["233"],"URL":"https:\/\/doi.org\/10.1186\/s13044-025-00233-y","relation":{},"ISSN":["1756-6614"],"issn-type":[{"value":"1756-6614","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"3 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"GJK\u2019s institution, The Johannes Gutenberg University (JGU) Medical Center, received research-associated funding from Merck Healthcare KGaA, Darmstadt, Germany.  LP received fees for seminars\/congresses from Merck and Sandoz.  YL declared no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='BoldItalic' removed-->Competing interests"}}],"article-number":"20"}}